Third-party lab testing: 4 independent Janoshik assays on file, covering 4 substances, median measured purity 99.8%, most recent test 2025-10-01.
Alluvi is listed as active. Identified through Janoshik third-party lab testing: 4 assays on file, most recent 2025-10-01.
| Substance | Measured purity | Test date |
|---|---|---|
| ALLUVI RETATRUTIDE 40MG KIT | 99.86% | 2025-10-01 |
| ALLUVI RETATRUTIDE 20MG KIT | 99.69% | 2025-10-01 |
| ALLUVI TIRZEPATIDE 20MG KIT | 99.79% | 2025-09-24 |
| ALLUVI TIRZEPATIDE 40MG KIT | 99.92% | 2025-09-24 |
| Status | Active |
|---|---|
| Independent assays on file | 4 |
| Median measured purity | 99.8% |
| Certificates of analysis | Vendor states COAs are available |
| Vendor type | Research-use supplier |
| Last tested | 2025-10-01 |
Alluvi is listed as active and we hold 4 independent Janoshik assays on file, median measured purity 99.8%. That is evidence about the batches that were tested or published, not a guarantee about the vial you receive.
Yes. We hold 4 third-party Janoshik assays for Alluvi, covering 4 substances, with a median measured purity of 99.8%. The most recent is dated 2025-10-01.
Popular peptides: Semaglutide, Tirzepatide, Retatrutide, BPC-157, CJC-1295, Ipamorelin.
Other reviewed vendors: Alpha Biologix Peptides Review, Alpha BioMed Peptides Review, Alpha BioPharma Peptides Review.